Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Raziel & Fosun Start Phase 3 Trial in China for Submental Fat Reduction Treatment
Details : RZL-012 is an injectable lipolytic drug, works by destroys fat cells and reduces fat volume, currently being developed for the reduction of unwanted submental fat in adults
Product Name : RZL-012
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2025
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
